The results of administering erlotinib and temsirolimus to adults suffering from recurrent, high-grade glioma in a phase-II trial were similar to those described above, and no correlation of survival with the presence of the mutation EGFRvIII, EGFR amplification, nor PTEN expression was observed [212]. Here, EGFR is linked to glioma.